Noaber Foundation

• Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction

  10 Sept 2026

• Timing-Dependent Clearance of p16-Positive Cells Mitigates Radiation-Induced Accelerated Aging

  1 Sept 2026

• Minimal measurement strategies for cardiometabolic risk classification within the Positive Health framework: A cross-sectional analysis of NHANES 1999-2004 data

  10 Aug 2026

• Senolytic-Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers

  1 Jan 2026

• Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice

  20 Nov 2025

• Senolytic-Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers

  30 Aug 2025

• Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases

  9 Oct 2024

• Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction

  12 Sept 2024

• Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era

  20 Aug 2021

• Sarcopenia: Aging-Related Loss of Muscle Mass and Function

  1 Jan 2019

Sources: api.crossref.org

• Fisetin is a senotherapeutic that extends health and lifespan

  EBioMedicine, 29 Sept 2018